In vitro antibacterial activity of chinfloxacin, a new fluoroquinolone antibiotic

Chemotherapy

Volumn 58, Issue 3, 2012, Pages 175-184

  Li, Guo Qing ^a   Yuan, Min ^a   Yang, Xin Yi ^a   Li, Cong Ran ^a   Hu, Xin Xin ^a   Zhang, Wei Xin ^a   Lou, Ren Hui ^a   Guo, Hui Yuan ^a   You, Xuan Wang ^b   Cen, Shan ^a   Jiang, Jian Dong ^a   You, Xue Fu ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b Zhangshu People's Hospital   (China)

Author keywords

Antibacterial activity; Chinfloxacin; Fluoroquinolones; In vitro studies

Indexed keywords

CHINFLOXACIN; CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

AGAR DILUTION; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CLINICAL EVALUATION; DRUG POTENCY; GRAM POSITIVE INFECTION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; STREPTOCOCCUS PYOGENES;

EID: 84862218464     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000337084     Document Type: Article

References (10)

1. Deitz WH, Bailey JH, Froelich EJ: In vitro antibacterial properties of nalidixic acid, a new drug active against gram-negative organisms. Antimicrob Agents Chemother (Bethesda) 1963;161:583-587.
2. Piddock LJ, Johnson M, Ricci V, Hill SL: Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Antimicrob Agents Chemother 1998;42:2956-2960. (Pubitemid 28501232)
3. Zhanel GG, Fontaine S, Adam H, Schurek K, Mayer M, Noreddin AM, Gin AS, Rubinstein E, Hoban DJ: A review of new fluoroquinolones: focus on their use in respiratory tract infections. Treat Respir Med 2006;5:437-465. (Pubitemid 46001331)
4. Mah FS: Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections. Curr Opin Ophthalmol 2004;15:316-320. (Pubitemid 38962111)
5. De Souza MV, Vasconcelos TR, de Almeida MV, Cardoso SH: Fluoroquinolones: an important class of antibiotics against tuberculosis. Curr Med Chem 2006;13:455-463.
6. Wang J, Xiao Y, Huang W, Xu N, Bai C, Xiu Q, Mei C, Zheng Q: A phase II study of antofloxacin hydrochloride, a novel fluoroquinolone, for the treatment of acute bacterial infections. Chemotherapy 2010;56:378-385.
7. Wagenlehner FM, Wagenlehner CM, Blenk B, Blenk H, Schubert S, Dalhoff A, Naber KG: Urinary pharmacokinetics and bactericidal activity of finafloxacin (200 and 800 mg) in healthy volunteers receiving a single oral dose. Chemotherapy 2011;57:97-107.
8. NCCLS: Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline. NCCLS document M26-A. Wayne, National Committee for Clinical Laboratory Standards, 1999.
9. CLSI: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard, ed 8. CLSI document M07-A8. Wayne, Clinical and Laboratory Standards Institute, 2009.
10. CLSI: Performance Standards for Antimicrobial Susceptibility Testing;19th Informational Supplement. CLSI document M100-S19. Wayne, Clinical and Laboratory Standards Institute, 2009.